|
C6ORF192 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.176230E-04 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.583500E-03 |
| Stage1-vs-Stage3 |
1.036990E-01 |
| Stage1-vs-Stage4 |
1.70822999999709E-05 |
| Stage2-vs-Stage3 |
4.806300E-04 |
| Stage2-vs-Stage4 |
1.29449999997089E-06 |
| Stage3-vs-Stage4 |
1.718150E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.63180580159406E-12 |
| Normal-vs-Asian |
1.79167791714008E-12 |
| Caucasian-vs-AfricanAmerican |
6.035200E-01 |
| Caucasian-vs-Asian |
5.107800E-01 |
| AfricanAmerican-vs-Asian |
4.411400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.678200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
3.33066907387547E-15 |
| Normal-vs-Age(81-100Yrs) |
2.22030000052165E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.514600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.498200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.426400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.773440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.912400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.442200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.561900E-04 |
| Classical-VS-Follicular |
2.95840000275049E-08 |
| Classical-VS-Other |
7.821000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.2569945084806E-11 |
| Tall-VS-Other |
4.203000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.622000E-02 |
| Follicular-VS-Normal |
3.31099999995033E-06 |
| Other-VS-Normal |
6.38289999743691E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.29709999996397E-06 |
|
|
